General Information of Drug Therapeutic Target (DTT) (ID: TTKSAQZ)

DTT Name Tankyrase (TNKS)
Gene Name TNKS
DTT Type
Clinical trial target
[1]
BioChemical Class
Glycosyltransferases
UniProt ID
NOUNIPROTAC
TTD ID
T83059
Function
Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length. Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. May be involved in spindle pole assembly through PARsylation of NUMA1. Stimulates 26S proteasome activity.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2X-121 DMX9MSL Breast cancer 2C60-2C65 Phase 2 [1]
BGB-290 DMRO6XT Ovarian cancer 2C73 Phase 2 [2]
STP1002 DMXCJP8 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 National Cancer Institute Drug Dictionary (drug id 769217).
3 Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171.